Background Telemedicine is a useful tool in the control of patients with rheumatological conditions, even more so in the pandemic period. The evolution of patients with rheumatoid arthritis (RA) treated exclusively under this modality has been scarcely described. Objectives Evolution of clinical activity in RA patients controlled exclusively by the synchronous telemedicine (ST) modality in the COVID-19 pandemic period. Methods An observational study was carried out.Two group of patients were analyzed separately, first group who had been treated using ST before the declaration of a health emergency in Colombia in march 2020 and second who were admitted to ST after this date. ST consists of a real-time video call with a trained general physician help on the referral site to performed physical examination. Assessments of disease activity was measured by DAS28 using C-reactive protein. Results Data was obtained from 150 and 65 patients in the first and second group. For the first group, more than a half of the patients had 2 controls with DAS28 assessment after march 2020, only 33% obtained 3 assessments, and very few with 4 or more. We found that the number of patients with high activity decreased significantly from 10% to 3%, remission increased from 44% to 50% and low activity from 14% to 19%, without major changes in the moderate activity group that remained close to a third. Same tendencies happened in group 2, with a difference in reduction of the moderate activity group from 44% to 38% (Figure 1). Conclusion When in person attention with rheumatologist is not possible, telemedicine is a useful and efficient way to control patients with RA, mainly finding a reduction in high activity and an increase patients in remission. References [1]Jhon A. McDougall .Telerheumatology: A Systematc Review. Arthrits Care and Research Vol 69, No October 2017, pp 1546-1557 [2]Luis Cajas. Description of a tele-rheumatology service in a Colombian institution. Rev Colomb Reumatol 2021; 28(3):161-170 Disclosure of Interests LUIS JAVIER CAJAS SANTANA Speakers bureau: Pfzer, Bristol, Janssen, Diego Cajas: None declared